Log In
BCIQ
Print this Print this
 

erenumab (AMG 334)

  Manage Alerts
Collapse Summary General Information
Company Amgen Inc.
DescriptionHuman mAb inhibiting the receptor for calcitonin gene-related peptide (CGRP)
Molecular Target Calcitonin gene-related peptide (CGRP) receptor
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase III
Standard IndicationMigraine
Indication DetailsPrevent episodic migraine; Treat migraine
Regulatory Designation
PartnerNovartis AG

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

09/01/2015

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today